Here are the DEF 14A proxy statements from Kestra Medical Technologies, Ltd. (KMTS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow KMTS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KMTS filings page.
Kestra Medical Technologies, Ltd. will hold its 2026 Annual General Meeting on September 9, 2026 at 9:00 a.m. Eastern Time, conducted as a virtual-only webcast at www.virtualshareholdermeeting.com/KMTS2026. Shareholders of record at the close of business on July 17, 2026 may attend and vote.
Shareholders are asked to elect three Class II directors (Traci S. Umberger, Raymond W. Cohen, and Kevin Reilly) to terms ending in 2029 and to ratify PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending April 30, 2027. The proxy materials outline a classified eight‑member board, committee structures, related‑party transactions, and detailed 2026 executive pay, including $7,501,904 in total compensation for CEO Brian Webster. Kestra is an emerging growth company, so no advisory vote on executive compensation is included.